ArticleDiabetes spectrum : a publication of the American Diabetes Association2017
Treatment of Obesity in Patients With Diabetes.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Short-chain fatty acids and insulin sensitivity: a systematic review and meta-analysis.Nutrition reviews · 2024Pooled it
- Health-related quality of life in racial and ethnic minority adults with type 2 diabetes: validity and responsiveness of the EQ-5D-3L.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Trial
- Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Association Between Changes in Body Composition and Physical Function After Intensive Behavioral Weight-loss Intervention: A Look AHEAD Trial Subgroup Analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Trial
- Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.Diabetes, obesity & metabolism · 2025Trial
- Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.Obesity (Silver Spring, Md.) · 2020Trial
- Article
- Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study.Journal of the National Cancer Institute · 2025Article
- Exploring the therapeutic potential of extract in targeting localized adiposity.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Novel Model Predicts Type 2 Diabetes Mellitus Patients Complicated With Metabolic Syndrome Using Retrospective Dataset From First Affiliated Hospital of Shenzhen University, China.International journal of endocrinology · 2025Article
- Adolescents' Diabetes Self-Management Regimens and Outcomes During the COVID-19 Pandemic: A Scoping Review.Cureus · 2024Review
- Review
- Low-carbohydrate diet for people with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2024Article
- Experiences of living with overweight/obesity and early type 2 diabetes in Singapore-a qualitative interview study.BMJ open · 2024Article
- Patient perspectives about treatment preferences for obesity with complications.Obesity science & practice · 2024Article
- Web-Based Intervention to Act for Weight Loss in Adults With Type 2 Diabetes With Obesity (Chance2Act): Protocol for a Nonrandomized Controlled Trial.JMIR research protocols · 2024Article
- Impacts of dietary animal and plant protein on weight and glycemic control in health, obesity and type 2 diabetes: friend or foe?Frontiers in endocrinology · 2024Review
- Retatrutide.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Obesity Duration and Cardiometabolic Disease.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives.Frontiers in clinical diabetes and healthcare · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.